BRAF-inhibitor-induced expression of FGF1 was furthermore seen in an independent publicly available dataset using melanoma cell lines, which were treated with 0.25 μM vemurafenib for 8 h (Fig. 3c)27. This evidence concerns the gene FGF1 and melanoma.